title: Baicalein attenuates proteasome inhibition-induced apoptosis by suppressing the activation of the mitochondrial pathway and the caspase-8- and Bid-dependent pathways.
abstract: Impairment in ubiquitin-proteasome system has been shown to be implicated in the pathogenesis in neurodegenerative disorders, such as Parkinson's disease. Flavonoid baicalein has demonstrated anti-oxidant and anti-inflammatory effects. However, the effect of baicalein on the neuronal cell death due to proteasome inhibition has not been studied. Thus, in the respect of the cell death process, we assessed the effect of baicalein on the proteasome inhibition-induced apoptosis using differentiated PC12 cells. The proteasome inhibitors MG132 and MG115 induced a decrease in Bid, Bcl-2, Bcl-xL and survivin protein levels, an increase in Bax levels, loss of the mitochondrial transmembrane potential, release of cytochrome c, activation of caspases (-8, -9 and -3), an increase in the tumor suppressor p53 levels and cleavage of PARP-1. Baicalein attenuated the proteasome inhibition-induced changes in the levels of apoptosis-related proteins, formation of reactive oxygen species, depletion of GSH, DNA damage and cell death. The results show that baicalein may attenuate the proteasome inhibition-induced apoptosis in PC12 cells by suppressing the activation of the mitochondrial pathway and the caspase-8- and Bid-dependent pathways. The preventive effect appears to be attributed to its inhibitory effect on the formation of reactive oxygen species and depletion of GSH.
authors.affiliation: Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul 156-756, South Korea.
authors.forename: Eun Byul
authors.initials: EB
authors.lastname: Jung
authors.affiliation: Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul 156-756, South Korea. Electronic address: leecs@cau.ac.kr.
authors.forename: Chung Soo
authors.initials: CS
authors.lastname: Lee
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D051023:BH3 Interacting Domain Death Agonist Protein / Q000378:metabolism*; D053181:Caspase 8 / Q000378:metabolism*; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D002467:Cell Nucleus / Q000187:drug effects; D044950:Flavanones / Q000494:pharmacology*; D005978:Glutathione / Q000378:metabolism; D007976:Leupeptins / Q000494:pharmacology; D008928:Mitochondria / Q000187:drug effects* / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D061988:Proteasome Inhibitors / Q000494:pharmacology*; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism
chemical_list: D051023:BH3 Interacting Domain Death Agonist Protein; D044950:Flavanones; D007976:Leupeptins; D061988:Proteasome Inhibitors; D017382:Reactive Oxygen Species; C089486:carbobenzoxy-leucyl-leucyl-norvalinal; C006680:baicalein; D053181:Caspase 8; D046988:Proteasome Endopeptidase Complex; D005978:Glutathione; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde
keywords: 2′,7′-Dichlorofluorescin diacetate (Sigma-Aldrich Inc. CID 77718); 3,3′-Dihexyloxacarbocyanine iodide (Sigma-Aldrich Inc. CID 9894321); 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich Inc. CID 3634887); Antibodies (Bid, Bax, Bcl-2, Bcl-xL, survivin, cytochrome c, PARP-1 and p53; Apoptosis-related proteins; Assay kit for rat/mouse cytochrome c (R&D systems); Assay kits for caspases-8, -9 and -3 (R&D systems); Baicalein; Baicalein (EMD-Calbiochem Pubchem CID 5281605); Differentiated PC12 cells; MG115 (Sigma-Aldrich Inc. CID 9868928); MG132 (Sigma-Aldrich Inc. CID 462382); Proteasome inhibition; Protection; Santa Cruz Biotechnology, Inc); TiterTACS™ colorimetric apoptosis detection kit (TrevigenInc.)